Optimising Care of Elderly Breast Cancer Patients: a Challenging Priority

Tipples, K. H.; Robinson, A.

doi:10.1016/j.clon.2008.11.015

Cited by 9 publications

(18 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, there is an increased frequency in comorbidities with increasing age; 35% of patients aged 65-79 years have at least 2 comorbid illnesses, as do 70% of those over 80 years of age (Tipples and Robinson, 2009). Both age and number of comorbid conditions are independently strong indicators of treatment options offered by clinicians.…”

Section: Discussionmentioning

confidence: 87%

“…Multiple studies indicate that elderly women receive less aggressive primary therapy, including fever axillary dissections ( esseler and Seton, 1978;August et al, 1994;Wanebo et al, 1997;Downey et al, 2007;Malik et al, 2013;Guth et al, 2013). The perceptions of potential morbidity from surgery and lack of benefit from adjuvant systemic therapy have resulted in omission of axillary surgery in elderly patients (Passage and McCarthy, 2007;Tipples and Robinson, 2009;Tang et al, 2011). However, inadequate axillary treatment has been shown to lead to increased rates of recurrence (Fisher at al., 2002;Passage and McCarthy, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, age is a dominant risk factor in the development of BC. Approximately onethird of BC patients are women >70 years old, and half are >65 years old (Tipples and Robinson, 2009;Vrana et al, 2013). Despite the fact that BC is a significant cause of morbidity and mortality in elderly women, many trials on which clinical practice is based have been conducted in younger populations, resulting in an under-representation of older patients (Tang et al, 2011;Güth et al, 2013;Mohamed and Muhamad, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Although relatively little is known about possible differences in the biology of BC in older patients compared to younger patients, it has been reported that advanced age is associated with less aggressive tumor features (Tipples and Robinson, 2009;Tang et al, 2011;Thomas and Leonard, 2009;Wildiers, 2008;Rao et al, 2007;Thapa et al, 2013;Zhao et al, 2014). In addition, an understanding of the relationship between age and life expectancy is vital in making clinical decisions regarding treatment (Rao et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Distinct Postsurgical Management in Young and Elderly Breast Cancer Patients Results in Equal Survival Rates

Oran

Yankol²,

Soybir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Although breast cancer (BC) is one of the most common malignant diseases in women, the majority of the studies describing the characteristics of BC in elderly patients have been limited to survival assessments or tumor features, without using younger BC patients as a reference group. The aim of our study was to describe and compare tumor characteristics and management patterns in elderly versus younger breast cancer patients in Turkey. Materials and Methods: We retrospectively analyzed 152 patients with invasive breast cancer who underwent surgery in our institution between 2002 and 2012. Patients were divided into 2 groups according to age at the time of diagnosis. Results: There were 62 patients in the elderly group (≥65 years) and 90 patients in the younger group (<65 years). Compared to the younger group, tumors in the elderly group were more likely to be larger (p=0.018), of lower grade (p=0.005), and hormone receptor-positive (p>0.001). There were no significant differences regarding histology, localization, lymph node involvement, or types of surgical procedures between the 2 groups. Comorbidities were more common in elderly patients (p<0.001). In addition, elderly patients were more likely to receive hormonal therapy (p<0.001) and less likely to receive radiotherapy (p=0.08) and chemotherapy (p=0.003). There was no difference in survival and locoregional recurrence rates between the groups. Conclusions: The results of this study demonstrate that breast cancer in elderly patients has more favorable tumor features, warranting less aggressive treatment regimens after surgery.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Distinct Postsurgical Management in Young and Elderly Breast Cancer Patients Results in Equal Survival Rates

Oran

Yankol²,

Soybir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In the last decade, the AIs have led to a longer disease-free survival (DFS) interval and lower distant relapse rates than with tamoxifen. The large pivotal trials illustrating these results did include women age Ͼ70 [25,26]; in general, benefit was found with AIs regardless of age [27]. Thus, there is evidence that older women should be offered 5 years of endocrine treatment for hormone receptor-positive breast cancer, and AIs are preferable.…”

Section: Elderly Women and Adjuvant Endocrine Treatmentmentioning

confidence: 99%

Early Breast Cancer in the Older Woman

Gandhi

Verma

2011

The Oncologist

View full text Add to dashboard Cite

Background. Women aged >65 are generally underrepresented in early breast cancer studies. Therefore, the optimal management of this group of women remains less certain.Methods. A literature review of recently published trials, reviews, and practice guidelines outlining the surgical and adjuvant management of early breast cancer in older women was performed.Results. Surgery remains as the cornerstone treatment for early breast cancer in the elderly. Adjuvant radiation is generally considered if the projected lifespan is >5 years. Hormone receptor-positive disease is best treated with adjuvant endocrine treatment; aromatase inhibitors and tamoxifen are both options. Evidence for the use of adjuvant

show abstract